BioWorld

Aug. 6, 2004

View Archived Issues

Portola Gains Cardio Program From Forebears At Millennium

Growing its cardiovascular research portfolio, Portola Pharmaceuticals Inc. in-licensed an antithrombosis program from Millennium Pharmaceuticals Inc., the company from which it was spun. (BioWorld Today) Read More

ICOS' Cialis Staying Strong In PDE5 Inhibitors Contest

Read More

Migrating Stem Cells Raise Hope For Stroke Treatments

Read More

Genoptix Approved Under CLIA For Personalized Medicine Work

Read More

Other News To Note

Read More

Appointments And Advancements

Read More